NASDAQ:PRPO

Precipio Competitors

$3.87
+0.02 (+0.52 %)
(As of 06/14/2021 11:19 AM ET)
Add
Compare
Today's Range
$3.76
$3.88
50-Day Range
$1.80
$5.25
52-Week Range
$0.92
$9.18
Volume5,752 shs
Average Volume6.76 million shs
Market Capitalization$87.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51

Precipio (NASDAQ:PRPO) Vs. ILMN, A, MTD, TXG, WAT, and AVTR

Should you be buying PRPO stock or one of its competitors? Companies in the industry of "analytical instruments" are considered alternatives and competitors to Precipio, including Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), 10x Genomics (TXG), Waters (WAT), and Avantor (AVTR).

Precipio (NASDAQ:PRPO) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Precipio has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Illumina has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

Profitability

This table compares Precipio and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-132.40%-64.20%-43.82%
Illumina18.14%14.81%9.02%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Precipio and Illumina, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
Illumina47602.12

Precipio currently has a consensus price target of $7.00, suggesting a potential upside of 81.82%. Illumina has a consensus price target of $374.50, suggesting a potential downside of 16.87%. Given Precipio's stronger consensus rating and higher probable upside, analysts clearly believe Precipio is more favorable than Illumina.

Earnings and Valuation

This table compares Precipio and Illumina's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$6.09 million14.43$-10,630,000.00N/AN/A
Illumina$3.24 billion20.30$656 million$4.50100.09

Illumina has higher revenue and earnings than Precipio.

Institutional & Insider Ownership

4.9% of Precipio shares are owned by institutional investors. Comparatively, 89.7% of Illumina shares are owned by institutional investors. 6.7% of Precipio shares are owned by insiders. Comparatively, 0.2% of Illumina shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Illumina beats Precipio on 8 of the 12 factors compared between the two stocks.

Precipio (NASDAQ:PRPO) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Precipio has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Profitability

This table compares Precipio and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-132.40%-64.20%-43.82%
Agilent Technologies15.90%24.14%11.98%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Precipio and Agilent Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
Agilent Technologies042002.83

Precipio currently has a consensus price target of $7.00, suggesting a potential upside of 81.82%. Agilent Technologies has a consensus price target of $112.0895, suggesting a potential downside of 22.13%. Given Precipio's stronger consensus rating and higher probable upside, analysts clearly believe Precipio is more favorable than Agilent Technologies.

Earnings and Valuation

This table compares Precipio and Agilent Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$6.09 million14.43$-10,630,000.00N/AN/A
Agilent Technologies$5.34 billion8.16$719 million$3.2843.79

Agilent Technologies has higher revenue and earnings than Precipio.

Institutional & Insider Ownership

4.9% of Precipio shares are owned by institutional investors. 6.7% of Precipio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Precipio (NASDAQ:PRPO) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Risk & Volatility

Precipio has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Profitability

This table compares Precipio and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-132.40%-64.20%-43.82%
Mettler-Toledo International20.19%195.99%23.93%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Precipio and Mettler-Toledo International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
Mettler-Toledo International23101.83

Precipio currently has a consensus price target of $7.00, suggesting a potential upside of 81.82%. Mettler-Toledo International has a consensus price target of $1,048.3333, suggesting a potential downside of 21.26%. Given Precipio's stronger consensus rating and higher probable upside, analysts clearly believe Precipio is more favorable than Mettler-Toledo International.

Earnings and Valuation

This table compares Precipio and Mettler-Toledo International's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$6.09 million14.43$-10,630,000.00N/AN/A
Mettler-Toledo International$3.09 billion10.04$602.74 million$25.7251.77

Mettler-Toledo International has higher revenue and earnings than Precipio.

Institutional & Insider Ownership

4.9% of Precipio shares are owned by institutional investors. Comparatively, 92.1% of Mettler-Toledo International shares are owned by institutional investors. 6.7% of Precipio shares are owned by insiders. Comparatively, 3.0% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Mettler-Toledo International beats Precipio on 6 of the 11 factors compared between the two stocks.

Precipio (NASDAQ:PRPO) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Earnings and Valuation

This table compares Precipio and 10x Genomics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precipio$6.09 million14.43$-10,630,000.00N/AN/A
10x Genomics$298.85 million70.59$-542,730,000.00($0.95)-202.23

Precipio has higher earnings, but lower revenue than 10x Genomics.

Profitability

This table compares Precipio and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precipio-132.40%-64.20%-43.82%
10x Genomics-160.22%-13.90%-10.73%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Precipio and 10x Genomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precipio00103.00
10x Genomics01602.86

Precipio currently has a consensus price target of $7.00, suggesting a potential upside of 81.82%. 10x Genomics has a consensus price target of $181.4444, suggesting a potential downside of 5.37%. Given Precipio's stronger consensus rating and higher probable upside, analysts clearly believe Precipio is more favorable than 10x Genomics.

Risk & Volatility

Precipio has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.

Institutional & Insider Ownership

4.9% of Precipio shares are owned by institutional investors. Comparatively, 68.7% of 10x Genomics shares are owned by institutional investors. 6.7% of Precipio shares are owned by insiders. Comparatively, 11.6% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

10x Genomics beats Precipio on 7 of the 12 factors compared between the two stocks.

Waters (NYSE:WAT) and Precipio (NASDAQ:PRPO) are both computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Waters and Precipio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.37 billion8.73$521.57 million$9.0536.97
Precipio$6.09 million14.43$-10,630,000.00N/AN/A

Waters has higher revenue and earnings than Precipio.

Profitability

This table compares Waters and Precipio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Waters24.56%1,107.70%22.37%
Precipio-132.40%-64.20%-43.82%

Analyst Ratings

This is a summary of current recommendations for Waters and Precipio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Waters37101.82
Precipio00103.00

Waters currently has a consensus target price of $251.25, suggesting a potential downside of 24.86%. Precipio has a consensus target price of $7.00, suggesting a potential upside of 81.82%. Given Precipio's stronger consensus rating and higher possible upside, analysts plainly believe Precipio is more favorable than Waters.

Volatility and Risk

Waters has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Precipio has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.

Institutional & Insider Ownership

87.4% of Waters shares are owned by institutional investors. Comparatively, 4.9% of Precipio shares are owned by institutional investors. 1.1% of Waters shares are owned by company insiders. Comparatively, 6.7% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Waters beats Precipio on 6 of the 11 factors compared between the two stocks.

Avantor (NYSE:AVTR) and Precipio (NASDAQ:PRPO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Avantor and Precipio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avantor$6.39 billion3.02$116.60 million$0.8937.30
Precipio$6.09 million14.43$-10,630,000.00N/AN/A

Avantor has higher revenue and earnings than Precipio.

Profitability

This table compares Avantor and Precipio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avantor3.51%41.17%6.84%
Precipio-132.40%-64.20%-43.82%

Analyst Ratings

This is a summary of current recommendations for Avantor and Precipio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avantor011302.93
Precipio00103.00

Avantor currently has a consensus target price of $35.1875, suggesting a potential upside of 6.02%. Precipio has a consensus target price of $7.00, suggesting a potential upside of 81.82%. Given Precipio's stronger consensus rating and higher possible upside, analysts plainly believe Precipio is more favorable than Avantor.

Volatility and Risk

Avantor has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Precipio has a beta of 2.51, meaning that its stock price is 151% more volatile than the S&P 500.

Institutional & Insider Ownership

92.4% of Avantor shares are owned by institutional investors. Comparatively, 4.9% of Precipio shares are owned by institutional investors. 2.0% of Avantor shares are owned by company insiders. Comparatively, 6.7% of Precipio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Avantor beats Precipio on 7 of the 12 factors compared between the two stocks.


Precipio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Illumina logo
ILMN
Illumina
1.2$450.42+0.6%$66.16 billion$3.24 billion105.24
Agilent Technologies logo
A
Agilent Technologies
1.7$143.63+0.1%$43.55 billion$5.34 billion48.20
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.1$1,331.46+0.4%$30.84 billion$3.09 billion48.86
10x Genomics logo
TXG
10x Genomics
1.4$192.12+0.7%$20.99 billion$298.85 million-38.12
Waters logo
WAT
Waters
1.3$334.57+0.6%$20.59 billion$2.37 billion33.90
Avantor logo
AVTR
Avantor
1.7$33.20+0.7%$19.46 billion$6.39 billion114.48Decrease in Short Interest
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.6$601.19+0.1%$17.91 billion$2.55 billion4.42
BIO.B
Bio-Rad Laboratories
0.7$579.60+0.0%$17.25 billion$2.55 billion4.26
PerkinElmer logo
PKI
PerkinElmer
1.9$146.65+0.1%$16.46 billion$3.78 billion15.36Insider Selling
Bruker logo
BRKR
Bruker
1.6$74.31+1.1%$11.14 billion$1.99 billion55.87Decrease in Short Interest
Coherent logo
COHR
Coherent
1.4$267.29+0.7%$6.51 billion$1.23 billion-41.00
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.7$29.61+1.3%$5.80 billion$78.89 million-80.02
OLK
Olink Holding AB (publ)
1.0$35.20+1.7%$4.26 billion$54.07 million0.00
Berkeley Lights logo
BLI
Berkeley Lights
1.4$47.29+3.2%$3.26 billion$64.30 million-9.77
Quanterix logo
QTRX
Quanterix
1.2$68.70+3.2%$2.42 billion$86.38 million-72.32
Bionano Genomics logo
BNGO
Bionano Genomics
1.0$8.08+6.2%$2.11 billion$8.50 million-29.93
OMIC
Singular Genomics Systems
0.0$25.10+0.9%$1.73 billionN/A0.00
Accelerate Diagnostics logo
AXDX
Accelerate Diagnostics
1.6$9.08+3.6%$534.14 million$11.16 million-6.39
Fluidigm logo
FLDM
Fluidigm
1.8$6.11+0.2%$457.27 million$138.14 million-8.15
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$7.60+0.5%$305.27 million$102.10 million-69.09
EyePoint Pharmaceuticals logo
EYPT
EyePoint Pharmaceuticals
1.7$9.85+3.6%$273.04 million$34.44 million-3.43Gap Up
Talis Biomedical logo
TLIS
Talis Biomedical
1.9$11.21+3.9%$265.61 million$10.94 million0.00Gap Up
Astrotech logo
ASTC
Astrotech
0.5$1.27+0.0%$62.85 million$490,000.00-1.67
HTG Molecular Diagnostics logo
HTGM
HTG Molecular Diagnostics
1.4$4.81+2.9%$29.29 million$8.55 million-1.09Increase in Short Interest
News Coverage
This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.